Light-adjustable IOLs provide stable outcomes

Article

Light-adjustable intraocular lenses (IOLs) provide near-emmetropic refractive outcomes and good uncorrected distance visual acuity that remains stable over time, according to a recent study.

Light-adjustable intraocular lenses (IOLs) provide near-emmetropic refractive outcomes and good uncorrected distance visual acuity that remains stable over time, according to a study published in the Journal of Cataract and Refractive Surgery.

Researchers at University Hospital Virgen de la Arrixaca, Murcia, Spain, performed a prospective non-randomized clinical trial of 53 eyes in 49 patients that had been implanted with a light-adjustable IOL. The researchers used spatial intensity profiles to correct refractive errors in the eyes, and estimated the effective changes in the IOLs' refraction after every treatment by subtracting those in the whole eye and the cornea.

After every light treatment and at 3-, 6- and 12-months, the researchers measured the refractive changes in the whole eye, refractive changes in the IOL, manifest refraction and visual acuity.

A maximum change in spherical power of the light-adjustable IOL of between −1.98 D and +2.30 D was induced by the combination of 2 light adjustments. In astigmatism the maximum change was up to −2.68 D. Axis errors were below 9 degrees. A small myopic shift of +0.01 to +0.57 D was produced by the 2 'lock-in' procedures.

To read an abstract of the study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.